Fundraising FoxPike Therapeutics
Vancouver, US · Founded 2019 · British Columbia, Canada corporation
Find your way into Pike Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
118 people can intro you to IAN
Ask David Kirk to introduce you to IAN FODIE
You →David · together at University of Otago →IAN
Sign up to find every way you can get introduced to Pike Therapeutics
- Your email: who you already know at Pike Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Pike Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Pike develops a multi-day, continuous-delivery patch formulation of dronabinol to address non-motor symptoms in Parkinson's Disease and agitation in Alzheimer's and dementia patients.
Founders & leadership
IF
IAN FODIECHIEF FINANCIAL OFFICER, SECRETARYIan Fodie has over 30 years of experience in small to medium-sized businesses with international operations in intangible and real property, including more than 20 years in public company roles. He has served as a board member focused on corporate governance and financing.
BM
BRADLEY MILESCHIEF EXECUTIVE OFFICER
Board
MP
MARK PURDYBoard director
Reported raises · per SEC filings
Form D private placements$1M disclosed across 3 rounds · 2021–2026
▶$760KraisedJul 2026 · 5 investors · Other TechnologyRule 506(b)
▶$760KraisedJul 2026 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- IAN FODIEExecutive Officer, Director
- BRADLEY MILESExecutive Officer, Director
- MARK PURDYDirector
- Offering amount
- $760K
- Amount sold
- $760K
- First sale
- Jun 2026
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$100KraisedSep 2023 · 2 investors · Other TechnologyRule 506(b)
▶$100KraisedSep 2023 · 2 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- MARK PURDYDirector
- IAN FODIEExecutive Officer, Director
- BRADLEY MILESExecutive Officer, Director
- Offering amount
- $100K
- Amount sold
- $100K
- First sale
- Aug 2023
- Incorporated
- Corporation, British Columbia, Canada, 2019
- Federal exemptions
- 06b
▶$175KraisedSep 2021 · 4 investors · Other TechnologyRule 506(b)
▶$175KraisedSep 2021 · 4 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- MARK PURDYDirector
- IAN FODIEExecutive Officer, Director
- BRADLEY MILESExecutive Officer, Director
- Offering amount
- $175K
- Amount sold
- $175K
- First sale
- Aug 2021
- Incorporated
- Corporation, British Columbia, Canada, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Pike Therapeutics do?
- Pike develops a multi-day, continuous-delivery patch formulation of dronabinol to address non-motor symptoms in Parkinson's Disease and agitation in Alzheimer's and dementia patients.
- How much funding has Pike Therapeutics raised?
- Pike Therapeutics has disclosed $1M raised across 3 rounds.
- Where is Pike Therapeutics headquartered?
- Pike Therapeutics is headquartered in Vancouver, US.